Bringing Value News Today

While there are many contributing factors to our current healthcare crisis, at the heart of the problem is how we pay for healthcare drives what we get.

We need to come at the problem very differently if we ever expect to get meaningful healthcare access and clinical solutions for American consumers.

Cutting the site-neutral payment provisions from the Lower Costs, More Transparency Act is just the latest symptom of an illness that has plagued healthcare for decades.

Amazon’s new chronic disease management initiative will not cure all healthcare ills, but it is an example of an innovative solution to long-standing problems.

The industry must brace for further pushback from lawmakers, regulators, and other stakeholders who, emboldened by the IRA victory, continue to try to rein in big pharma.

For an industry in critical condition, failure to pivot to a new model is not optional: for better or worse, the next catalyst for change is coming.

Long standing economic, operational and other challenges will persist into 2024, with the net of these forces raising the need to pivot to a new patient-centered model.

The pharma landscape is more volatile than ever before, and pushback on drug prices will continue to intensify from payers, PBMs and especially consumers.

There is no easy fix to get us to a new market-based model in healthcare, but greater transparency must be the centerpiece of any reform.

Without a focused effort to clearly make the case for the true value of medicines and drug innovation, consumers negative perceptions about the industry will persist.